北京市贸促会党组书记、北京国际商会会长章建伟强调，本次活动是深化中外医疗产业合作的具体实 践。当前，北京医药健康产业规模已突破万亿，创新成果丰硕，正成为全球医药资源的"强磁场"。期待 以对接会为契机，推动北京创新药械、数字医疗技术与南亚市场需求精准链接，在采购、研发、转化等 领域形成务实成果，携手构建互利共赢的产业生态。 大兴区委常委，区政府党组副书记、副区长郭文杰表示，将全力服务产业出海，对接全球市场。活动紧 密围绕大兴区"6+5+3"产业发展布局，是天宫院街道与大兴生物医药产业基地深化"街园联动"、服务主 导产业、融入"一带一路"建设的生动实践。 12月16日，中国药谷·南亚医疗器械供需对接会在北京市大兴区营商服务中心成功举办。本次活动由商 务部外贸发展事务局、中国国际贸易促进委员会北京市分会联合主办，北京市大兴区商务局、大兴区投 资促进服务中心、大兴区天宫院街道办事处(京南物流基地管委会)、大兴生物医药产业基地管委会等相 关单位及机构共同承办。商务部外贸发展事务局副局长王德阳，北京市贸促会党组书记、北京国际商会 会长章建伟，北京市贸促会副主任、北京国际商会副会长兼秘书长朱家亮，商务部对外贸易司轻纺医药 ...

12月16日，中国药谷·南亚医疗器械供需对接会在北京市大兴区营商服务中心成功举办。本次活动由商 务部外贸发展事务局、中国国际贸易促进委员会北京市分会联合主办，北京市大兴区商务局、大兴区投 资促进服务中心、大兴区天宫院街道办事处(京南物流基地管委会)、大兴生物医药产业基地管委会等相 关单位及机构共同承办。商务部外贸发展事务局副局长王德阳，北京市贸促会党组书记、北京国际商会 会长章建伟，北京市贸促会副主任、北京国际商会副会长兼秘书长朱家亮，商务部对外贸易司轻纺医药 处李其卓，上海合作组织国家多功能经贸平台卫生可持续发展工作委员会秘书长杜江春，政协北京市大 兴区委员会党组书记、主席禹学垠，北京市大兴区委常委，区政府党组副书记、副区长郭文杰等领导出 席活动。印度驻北京大使馆贸易与商务二等秘书阿维纳什·纳格，马来西亚一带一路总商会总监程伟 文，尼泊尔化学与医疗供应商协会会长巴克塔·哈马尔，以及来自南亚、东南亚多国近30家采购商与国 内70余家医疗器械企业代表齐聚一堂，共同聚焦医疗器械领域的贸易与产业合作。活动旨在深度落 实"一带一路"倡议，为"中国药谷"与南亚各国搭建精准、务实的对接平台，现场达成多项合作共识，开 启了 ...

推进医疗器械临床研究成果转化暨"春雨行动"工作推进会召开 12月4日，国家药监局官微发文显示，日前，推进医疗器械临床研究成果转化暨"春雨行动"工作推进会 在广州召开。会议全面总结"春雨行动"阶段性成效，深入分析试点面临的困难，研究部署下一步工作安 排。会议要求，各参与试点省份要准确把握"春雨行动"的关键环节，继续加强政策宣贯培训，做好项目 征集和评估筛选，积极开展分类指导服务，推动项目匹配对接，完善跨部门协同工作机制，强化注册服 务能力建设，推进以临床价值为导向的医疗器械源头创新，推动"春雨行动"从试点省份探索转向全国常 态化运行，加快产品上市进程。 187个化药集采启动 政策动向 12月3日，中纪委官网发布要闻《来自监督一线的报道丨拧紧医保基金"安全阀"》谈到，在山西省太原 市纪委监委牵头推动下，太原市医保局开展了新一轮医保基金领域问题线索集中筛查。借助大数据信息 化技术，着力排查骗保、套保等问题线索，并进行实地检查核查，依规依法作出处理。 21点评：随着一桩桩骗保案被不断挖出，其背后的腐败链条也被斩断。在跨部门协同、大数据监管、严 肃问责与持续性整改的过程中，基金安全的防线也将更加坚实。 药械审批 新华医 ...

证券代码：600587 证券简称：新华医疗 公告编号：临2025-063 山东新华医疗器械股份有限公司 关于公司产品获得二类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）和控股子公司新华手术器械有限公司 于近日收到山东省药品监督管理局颁发的《中华人民共和国医疗器械注册证》，具体情况如下： 一、医疗器械注册证的具体情况 （一）手术无影灯 1、产品名称：手术无影灯 2、注册证编号：鲁械注准20252010721 3、注册人名称：山东新华医疗器械股份有限公司 4、注册人住所：山东省淄博市高新技术产业开发区新华医疗科技园 5、生产地址：淄博高新区齐祥路3588号 6、结构及组成：产品由灯头、悬臂组件和安装固定组件组成。其中安装固定组件包括基座和下延柱， 悬臂组件包括横譬和弹簧臂，灯头包括上弯管、下弯管、灯头主体、可拆卸手柄和臂控面板。 超薄蝶形外观，设计轻巧使用方便，满足手术室层流需求；高显色性医用LED光源，高质量还原日光色 彩；产品配备了R ...

（编辑 袁冠琳） 证券日报网讯 12月4日晚间，新华医疗发布公告称，山东新华医疗器械股份有限公司和控股子公司新华 手术器械有限公司于近日收到山东省药品监督管理局颁发的《中华人民共和国医疗器械注册证》，产品 名称分别为手术无影灯和胸腹腔内窥镜，注册证编号分别为鲁械注准20252010721和鲁械注准 20252060702。 ...

Group 1 - China Pacific Insurance has received approval from the financial regulatory authority for Wang Yuhua to serve as a director [1] - Shanghai Bank announced that the regulatory authority has approved Chen Lei's qualification as vice president [2] - Shanghai HuGong has decided to terminate the "Aerospace Equipment Manufacturing Base" fundraising project due to significant changes in project feasibility [3] Group 2 - Dongwang Times plans to reduce its stake by up to 1.20% through share sales [4] - Zhinancun intends to increase its capital by 100 million yuan in its wholly-owned subsidiary, Maigao Securities [5] - Jinxinnong reported a sales revenue of 115 million yuan from pig sales in November [6] Group 3 - Tiantan Biological has completed the Phase III clinical trial of its human prothrombin complex, showing good efficacy and safety for hemophilia B patients [7] - Beijete's subsidiary has signed a framework agreement for equity acquisition to gain control of Yunnan Wenye Nonferrous Metals [8] - Zhongsheng Pharmaceutical's RAY1225 injection has received approval for a new clinical trial indication for treating metabolic-associated fatty liver disease [9] Group 4 - Enhua Pharmaceutical's hydrochloride sulpiride tablets have passed the consistency evaluation for generic drugs [10] - Shenkong Co. plans to invest 60 million yuan in a semiconductor industry fund [11] - Lianhuan Pharmaceutical's subsidiary has received approval for its drug to pass the consistency evaluation for generic drugs [12] Group 5 - Dazhong Transportation has received approval to issue debt financing tools totaling 4.5 billion yuan [13] - Jintian Titanium Industry plans to invest 50 million yuan in an industry merger and acquisition fund [14] - Changchun Gas has committed over 1.7 billion yuan to gas facility upgrades [15] Group 6 - Laimei Pharmaceutical's innovative anti-cancer drug "Nano Carbon Iron" has received approval for clinical trials [16] - Longquan Co. has signed supply contracts worth approximately 50.76 million yuan for nuclear power components [17] - Igor plans to distribute a cash dividend of 1 yuan per 10 shares [18] Group 7 - Xingfa Group's subsidiary has signed a processing agreement for 80,000 tons of lithium iron phosphate [20] - Yunjigroup's director Wang Wanfeng has resigned for personal reasons [21] - Saiseng Pharmaceutical's application for the listing of a new drug has been accepted by the regulatory authority [22] Group 8 - Xinhua Medical has obtained registration certificates for two new medical devices [23] - Chaoying Electronics plans to invest 100 million USD in its Thai subsidiary for an AI circuit board expansion project [24] - Suzhou Planning's application to acquire 100% of Dongjin Aviation has been accepted by the Shenzhen Stock Exchange [25]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Dongxing Medical, which closed at 27.5 yuan with a PE ratio of 30.75 times, significantly lower than the industry average of 56.58 times [1][2] - Dongxing Medical's total market capitalization is 2.755 billion yuan, ranking 59th in the medical device industry based on PE ratio [1][2] - The company reported a revenue of 78.1865 million yuan for Q1 2025, reflecting a year-on-year decline of 14.84%, and a net profit of 12.064 million yuan, down 39.35% year-on-year, with a gross margin of 44.40% [1] Group 2 - The average PE ratio for the medical device industry is 56.58 times, with a median of 39.97 times, indicating that Dongxing Medical is undervalued compared to its peers [2] - The company specializes in the research, production, and sales of surgical medical devices, including products like endoscopic staplers and electric hydraulic surgical tables [1] - As of July 31, 2025, Dongxing Medical had 11,138 shareholders, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1]

Group 1 - The core viewpoint of the news is that Dongxing Medical's stock performance shows a decline in earnings and a low valuation compared to its industry peers, indicating potential investment concerns [1][2]. - Dongxing Medical's closing price on August 11 was 28.2 yuan, with a PE ratio of 31.53, marking a new low in 52 days and a total market capitalization of 2.825 billion yuan [1]. - The average PE ratio for the medical device industry is 56.56, with a median of 39.76, positioning Dongxing Medical at the 62nd rank within the industry [1]. Group 2 - As of July 31, 2025, Dongxing Medical has 11,138 shareholders, a decrease of 7 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1]. - The main business of Jiangsu Dongxing Smart Medical Technology Co., Ltd. includes the research, production, and sales of surgical medical devices, with key products such as endoscopic staplers and electric hydraulic surgical tables [1]. - The latest quarterly report for Q1 2025 shows Dongxing Medical achieved revenue of 78.1865 million yuan, a year-on-year decrease of 14.84%, and a net profit of 12.064 million yuan, down 39.35%, with a gross profit margin of 44.40% [1].

Company Overview - Dongxing Medical closed at 26.88 yuan, up 1.28%, with a rolling PE ratio of 30.05, marking a new low in 39 days, and a total market capitalization of 2.693 billion yuan [1] - The company ranks 58th in the medical device industry, which has an average PE ratio of 55.41 and a median of 37.94 [1] Shareholder Information - As of July 18, 2025, Dongxing Medical had 11,145 shareholders, a decrease of 347 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Business Operations - Dongxing Medical specializes in the research, production, and sales of surgical medical devices, with key products including laparoscopic staplers, open staplers, stapler components, electric hydraulic surgical tables, shadowless surgical lights, and delivery beds [1] Financial Performance - In the first quarter of 2025, the company reported revenue of 78.1865 million yuan, a year-on-year decrease of 14.84%, and a net profit of 12.064 million yuan, down 39.35%, with a gross margin of 44.40% [1] Industry Comparison - The PE ratios for Dongxing Medical and its peers are as follows: Dongxing Medical at 30.05, with the industry average at 55.41 and the median at 37.94 [2]

Company Overview - Dongxing Medical closed at 26.2 yuan on July 16, with a 2.34% increase, and a rolling PE ratio of 29.29, marking a new low in 27 days, with a total market value of 2.625 billion yuan [1] - The company's main business includes the research, production, and sales of surgical medical devices, with key products such as endoscopic staplers, open staplers, stapler components, electric hydraulic surgical tables, shadowless surgical lights, and delivery beds [1] Financial Performance - In the latest quarterly report for Q1 2025, Dongxing Medical reported operating revenue of 78.1865 million yuan, a year-on-year decrease of 14.84%, and a net profit of 12.064 million yuan, down 39.35%, with a gross profit margin of 44.40% [1] Industry Comparison - The average PE ratio for the medical device industry is 51.87, with a median of 37.48, placing Dongxing Medical at the 62nd position in the industry ranking [1] - The company's static PE ratio is 26.94, and its price-to-book ratio is 1.16 [2] - Other companies in the industry have varying PE ratios, with the highest being 19.04 for Antu Biology and the lowest at 10.85 for Jiuan Medical [2] Capital Flow - On July 16, Dongxing Medical experienced a net inflow of main funds amounting to 5.7309 million yuan, although it has seen a total outflow of 9.1392 million yuan over the past five days [1]